Silencing of CXCL12 Performs a Protective Effect on C5b-9-induced Injury in Podocytes

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2018 Mar 7

PMID 29508174

Citations 3

Authors

Wengang Sha

Lei Shen

Ling Zhou

Deyu Xu

Jing Yang

Guoyuan Lu

Affiliations

Soon will be listed here.

Abstract

Purpose: Podocytes, terminal differentiation cell in glomerulu, are crucial to kidney-related diseases such as membranous nephropathy (MN). MN is characterized by podocyte injury and glomerular basement membrane thickening. This paper focused to investigate the expression of chemokine (C-X-C motif) ligand 12 (CXCL12) in MN patients and its possible role in podocyte injury.

Methods: Through the enzyme-linked immunosorbent assay, CXCL12 level in the serum and urine of MN patients was examined. Further, several assays of cell viability, apoptosis, quantitative real-time PCR and western blot were applied to explore the effects of CXCL12 in the model of podocyte injury.

Results: We found a significant increase of CXCL12 in serum and urine of MN patients, which indicated that CXCL12 may be involved in the progression of MN. And in vitro C5b-9-induced podocyte injury model, the proliferation of podocytes was inhibited whereas CXCL12/CXCR4 and phosphorylated STAT3 (p-STAT3) were increased. Silencing of CXCL12 remarkably promoted cell proliferation, inhibited cell apoptosis and suppressed CXCL12/CXCR4, p-STAT3 and caspase 3. Consistently, STAT3 inhibitor and berberine (a CXCL12 antagonist) also reduced CXCL12 treatment-induced apoptosis.

Conclusions: All data suggested that silencing of CXCL12 had a protective effect on podocyte injury, which may be through inhibiting CXCL12/STAT3 signaling pathway.

Citing Articles

Review of molecular biological research on the treatment of membranous nephropathy with Tripterygium glycosides based on TCM theory.

Xu P, Fu G, Zhao H, Wang M, Ye H, Shi K Medicine (Baltimore). 2023; 102(45):e34686.

PMID: 37960769 PMC: 10637535. DOI: 10.1097/MD.0000000000034686.

Advances of berberine against metabolic syndrome-associated kidney disease: Regarding effect and mechanism.

Liu Y, Wang H, Geng Y, Han L, Tu S, Wang H Front Pharmacol. 2023; 14:1112088.

PMID: 36814494 PMC: 9939707. DOI: 10.3389/fphar.2023.1112088.

Mechanism of action of for treatment of idiopathic membranous nephropathy based on network pharmacology.

Shi H, Hou Y, Su X, Qiao J, Wang Q, Guo X Ren Fail. 2022; 44(1):116-125.

PMID: 35172688 PMC: 8856020. DOI: 10.1080/0886022X.2021.2024850.

References

Prunotto M, Carnevali M, Candiano G, Murtas C, Bruschi M, Corradini E . Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol. 2010; 21(3):507-19. PMC: 2831859. DOI: 10.1681/ASN.2008121259. View

Lutticken C, Wegenka U, Yuan J, Buschmann J, Schindler C, Ziemiecki A . Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science. 1994; 263(5143):89-92. DOI: 10.1126/science.8272872. View

Hong J, Kang B, Kim A, Hwang S, Ahn J, Lee S . Development of a highly sensitive real-time one step RT-PCR combined complementary locked primer technology and conjugated minor groove binder probe. Virol J. 2011; 8:330. PMC: 3142241. DOI: 10.1186/1743-422X-8-330. View

Zhang W, Chen X, Shi S, Wei R, Wang J, Yamanaka N . Expression and activation of STAT3 in chronic proliferative immune complex glomerulonephritis and the effect of fosinopril. Nephrol Dial Transplant. 2005; 20(5):892-901. DOI: 10.1093/ndt/gfh652. View

Lesina M, Kurkowski M, Ludes K, Rose-John S, Treiber M, Kloppel G . Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011; 19(4):456-69. DOI: 10.1016/j.ccr.2011.03.009. View

Bruschi M, Carnevali M, Murtas C, Candiano G, Petretto A, Prunotto M . Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. J Proteomics. 2011; 74(10):2008-17. DOI: 10.1016/j.jprot.2011.05.021. View

Ayalon R, Beck Jr L . Membranous nephropathy: not just a disease for adults. Pediatr Nephrol. 2013; 30(1):31-9. PMC: 4074564. DOI: 10.1007/s00467-013-2717-z. View

Greenhill C, Rose-John S, Lissilaa R, Ferlin W, Ernst M, Hertzog P . IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol. 2010; 186(2):1199-208. DOI: 10.4049/jimmunol.1002971. View

Burns J, Summers B, Wang Y, Melikian A, Berahovich R, Miao Z . A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006; 203(9):2201-13. PMC: 2118398. DOI: 10.1084/jem.20052144. View

10.

Sinico R, Mezzina N, Trezzi B, Ghiggeri G, Radice A . Immunology of membranous nephropathy: from animal models to humans. Clin Exp Immunol. 2015; 183(2):157-65. PMC: 4711165. DOI: 10.1111/cei.12729. View

11.

Stark G, Darnell Jr J . The JAK-STAT pathway at twenty. Immunity. 2012; 36(4):503-14. PMC: 3909993. DOI: 10.1016/j.immuni.2012.03.013. View

12.

Lo C, Chen M, Hsiao M, Wang S, Chen C, Hsiao S . IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2010; 71(2):424-34. DOI: 10.1158/0008-5472.CAN-10-1496. View

13.

Beck Jr L, Bonegio R, Lambeau G, Beck D, Powell D, Cummins T . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361(1):11-21. PMC: 2762083. DOI: 10.1056/NEJMoa0810457. View

14.

Arakawa T, Masaki T, Hirai T, Doi S, Kuratsune M, Arihiro K . Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis. Nephrol Dial Transplant. 2008; 23(11):3418-26. DOI: 10.1093/ndt/gfn314. View

15.

Ma H, Sandor D, Beck Jr L . The role of complement in membranous nephropathy. Semin Nephrol. 2013; 33(6):531-42. PMC: 4274996. DOI: 10.1016/j.semnephrol.2013.08.004. View

16.

Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann J, Bensman A . Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002; 346(26):2053-60. DOI: 10.1056/NEJMoa012895. View

17.

Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C . Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol. 2003; 14(7):1851-7. DOI: 10.1097/01.asn.0000071511.35221.b3. View

18.

Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S . Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000; 6(5):583-8. DOI: 10.1038/75068. View

19.

Gutwein P, Abdel-Bakky M, Schramme A, Doberstein K, Kampfer-Kolb N, Amann K . CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J Pathol. 2009; 174(6):2061-72. PMC: 2684172. DOI: 10.2353/ajpath.2009.080960. View

20.

Sayyed S, Hagele H, Kulkarni O, Endlich K, Segerer S, Eulberg D . Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia. 2009; 52(11):2445-54. DOI: 10.1007/s00125-009-1493-6. View